EGFR and neoplasm: Indeed, analyses of larger cohorts of pre-treatment EGFRM+ LAC samples not only confirm that TP53 mutations are among the most frequent (>50%) concomitant alterations in this cancer type [12], but also show that they are associated with significantly faster tumor progression after treatment with EGFR-TKIs of all three generations [38,124].